about
Mechanisms of apoptosis by the tumor suppressor Par-4Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice.Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologicallyProstate apoptosis response-4 mediates TGF-β-induced epithelial-to-mesenchymal transition.Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity.Cancer-selective apoptotic effects of extracellular and intracellular Par-4.Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.Expression Pattern of the Pro-apoptotic Gene PAR-4 During the Morphogenesis of MCF-10A Human Mammary Epithelial Cells.Plant-derived SAC domain of PAR-4 (Prostate Apoptosis Response 4) exhibits growth inhibitory effects in prostate cancer cellsStructural basis for the regulatory interactions of proapoptotic Par-4.Cloning, expression, purification, crystallization and preliminary crystallographic analysis of the C-terminal domain of Par-4 (PAWR).Two-state conformational equilibrium in the Par-4 leucine zipper domain.There is more to a lipid than just being a fat: sphingolipid-guided differentiation of oligodendroglial lineage from embryonic stem cells.Intrinsic disorder and coiled-coil formation in prostate apoptosis response factor 4.Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas.Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.Recombinant Production and Characterization of SAC, the Core Domain of Par-4, by SUMO Fusion System.Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
P2860
Q27011309-B330C2F6-CC07-480F-AA81-44AACF723917Q33755247-0219418C-C245-4C03-AA3B-6A957C43F20FQ34031858-ADBC0CE9-8939-412C-A249-C024E04930EBQ34162371-2447D431-A250-420A-961F-535CC861D929Q37620729-C0589753-9A48-45E7-A646-03B9397883BEQ37714160-ACFF13FA-3CC6-42F3-8A40-55F578ED58BEQ37741771-52E2D442-AD2A-415F-852E-2C243BD67713Q39644350-160F170C-BB28-40A0-81D2-7BCD171F344AQ39757630-F2FE4A16-CEF5-4952-B92F-773F52585D3EQ41202282-1C78A7AE-7227-41A1-8E66-11CB7A47EB86Q41467308-EB28633C-E00E-46C8-AB92-13FCBFFA1C95Q42018401-85327F65-4C3F-4B55-9CF1-70BE1FFCE248Q42985847-782E9554-8568-4958-B590-ED2288BD8BFAQ43084069-A45B7693-3892-43B3-8D71-1C3ED9A703B6Q44135628-43FBD240-AF23-46C0-95FA-4D9157312D22Q45082063-E7CC5C6B-DE39-488B-A402-ED021660FDA8Q46970334-540C4536-0D74-4D3D-BAD8-ACE2807BDA70Q47608040-FA431E8B-18C7-492E-BC61-8B10D24EFEE6Q55553003-16AC5C64-060C-4B27-BC1C-803D33B4F3CA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Apoptosis and tumor resistance conferred by Par-4
@en
Apoptosis and tumor resistance conferred by Par-4.
@nl
type
label
Apoptosis and tumor resistance conferred by Par-4
@en
Apoptosis and tumor resistance conferred by Par-4.
@nl
prefLabel
Apoptosis and tumor resistance conferred by Par-4
@en
Apoptosis and tumor resistance conferred by Par-4.
@nl
P2860
P356
P1476
Apoptosis and tumor resistance conferred by Par-4
@en
P2093
Vivek M Rangnekar
Yanming Zhao
P2860
P304
P356
10.4161/CBT.7.12.6945
P577
2008-12-08T00:00:00Z